Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DTPA-omburtamab for Solid Tumor Leptomeningeal Metastasis
NCT04315246Phase 2Withdrawn
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of 177Lu-DTPA-omburtamab in leptomeningeal metastasis (LM), sponsored by Y-mAbs Therapeutics, Inc.. Planned start Aug 2022; status: withdrawn.
02
Drugs
177Lu-DTPA-omburtamab
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT04315246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315246.